啟迪藥業(000590.SZ)第三季度預盈900萬-1000萬元 同比增長63.90%-82.11%
格隆匯10月13日丨啟迪藥業(000590.SZ)公佈,預計2021年前三季度歸屬於上市公司股東的淨利潤3800萬元-4000萬元,同比增長96.63%-106.98%;其中,第三季度歸屬於上市公司股東的淨利潤900萬元-1000萬元,同比增長63.90%-82.11%。
公司2021年前三季度業績變動的主要原因系營業收入較上年同期增長約23%,相應影響淨利潤增長。除此外,其他收益及理財收入同比增加也是影響淨利潤增長的原因之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.